La inmunoterapia como cambio de paradigma - page 7

Immunotherapy in 2L treatment

of NSCLC patients

•

Randomized trials in 2L

docetaxel



Improved survival



Greater benefit in pts with PDL1+ tumors



New standard of care

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1,2,3,4,5,6 8,9,10,11,12,13,14,15,16,17,...28